Science for a Healthier Tomorrow
Science for a Healthier Tomorrow
Science for a Healthier Tomorrow
Two people can take the same GLP-1 weight-loss drug, follow the same instructions, and get completely different results. Three publications in the same week September 2026 converge on one bottom line: people's responses to these medicines vary widely, and much of that variation — like part of the drugs' heart protection — remains unexplained.
Pooled evidence from 37 studies and two withdrawal trials: about 0.4 kg regained per month after stopping (0.8 kg after semaglutide or tirzepatide), most lost weight typically returning within about a year, with cardiometabolic gains fading alongside — plus what remains projected, not measured. About 0.4 kg (about 0.9 lb) regained per month after stopping weight-loss medications — 0.8 kg (about 1.8 lb) after semaglutide or tirzepatide — and cardiometabolic gains fade too.
A preliminary 14-day controlled feeding trial found that a ~95% ultra-processed diet left GLP-1, PYY, ghrelin and PP responses unchanged in lean young adults — an exploratory, industry-partnership-funded null.
A meta-analysis of 51 cohorts links each extra 100 g/day of ultra-processed food to about 14% higher cardiovascular-event risk. What the low certainty rating and the missed hypertension null mean.
A preliminary pooled analysis of five time-restricted-eating trials (124 adults) found more weight loss with an 8-hour window — with caveats about subgroup size and statistical adjustment.
A randomized trial of provided meals found keto cut liver fat more at matched ~10% weight loss, while muscle insulin sensitivity rose ~50% in all three diets and LDL/ApoB showed no differences.
In a claims study of 2,031 youths starting GLP-1 drugs, 16.9% had a recorded nutritional deficiency within a year; 23.3% had a nutrition visit.